Welcome to our dedicated page for Pacira BioSciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Dimensional Fund Advisors reported beneficial ownership of 2,060,597 shares of Pacira BioSciences common stock, representing 5.1% of the class as of 03/31/2026. The filing states these shares are owned by investment company and other funds advised or sub‑advised by Dimensional, which disclaims beneficial ownership.
Pacira BioSciences (PCRX): The Vanguard Group files Amendment No. 12 to Schedule 13G/A reporting zero beneficial ownership in Common Stock. The filing states 0 shares and 0% ownership and explains an internal realignment effective January 12, 2026 that produced disaggregated reporting by Vanguard subsidiaries. The filing is signed by Ashley Grim on 03/27/2026 and lists Vanguard's Malvern address.
Pacira BioSciences director Mark A. Kronenfeld received an equity award of 6,163 restricted stock units on June 11, 2025. The grant was at no cash cost per share and increases his direct holdings to 31,065 common shares equivalents.
The units vest on June 11, 2026, only if he remains in continuous service with Pacira through that date. Each restricted stock unit converts into one share of Pacira common stock upon vesting, reflecting standard, service-based director compensation rather than an open-market purchase or sale.
Pacira BioSciences Chief Medical Officer Jonathan Slonin sold 3,261 shares of common stock in an open-market transaction at a price of $22.82 per share on March 17, 2026. After this sale, he directly holds 223,640.175 shares of Pacira common stock.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Slonin previously adopted, indicating the sale was scheduled in advance rather than timed discretionarily.
Pacira BioSciences, Inc. director Mark Froimson reported an open-market sale of 500 shares of common stock at $21.81 per share. After this transaction, he directly holds 20,136 shares. This filing reflects a relatively small sale compared with his remaining reported ownership.
PCRX files a Form 144 reporting proposed sale of Common Stock. The filing lists prior acquisitions of Common Stock: 209 shares purchased under an ESPP on 12/31/2021, 2,000 shares acquired on exercise of stock options on 05/23/2022, and 1,052 shares from restricted stock vesting on 06/03/2022. The notice identifies Fidelity Brokerage Services LLC as the broker.
Pacira BioSciences, Inc. is the target of an activist campaign by DOMA Perpetual Capital Management and affiliates, which report beneficial ownership of 2,936,794 common shares, or 7.3% of the company. The group, led by Pedro Escudero, filed Amendment No. 3 to Schedule 13D.
Using 40,489,894 shares outstanding as of February 23, 2026, DOMA and related entities disclose various stakes, including 4.9% held by Doma Perpetual LO Equity Master Fund and 2% reported for The John Templeton Foundation. On March 11, 2026, Doma Master Fund notified Pacira it intends to nominate three directors at the 2026 annual meeting and to solicit proxies.
In a March 12, 2026 press release incorporated in the filing, DOMA called for chief executive officer Frank Lee to be replaced and urged the board to appoint an interim CEO. DOMA also stated its view that Pacira’s stock price has declined over several years while expenses and management compensation have increased, and urged the board to run a formal sale process to maximize value for shareholders.
DOMA Perpetual announced a solicitation to nominate three director candidates to the board of Pacira BioSciences, Inc. and stated it beneficially owns approximately 7.3% of Pacira's common stock. The nominating group urges removal of CEO Frank Lee, requests an interim CEO and a formal sale process, and criticizes multi-year underperformance, management compensation changes to RSUs, and strategic decisions including relocation of headquarters. DOMA names nominees Christopher Dennis, Oliver Benton Curtis III and Eric de Armas, and says it will file a preliminary proxy statement and a WHITE universal proxy card to solicit votes at the 2026 annual meeting.
DOMA Perpetual is soliciting proxies to elect three nominees to the board of Pacira Biosciences and announced its intention to file a preliminary proxy statement and WHITE universal proxy card to be used at the 2026 annual meeting. In a Mar 11, 2026 press release, DOMA says it beneficially owns 7.1% of Pacira common stock and cites sustained underperformance, executive compensation concerns, and strategic disagreements.
DOMA requests the Board name an interim CEO, pursue a formal sale process for the company and replace CEO Frank Lee; it also nominates Christopher Dennis, Oliver Benton Curtis and Eric de Armas to address governance and strategic execution.